Tuberc Respir Dis.
2011 Oct;71(4):286-290.
Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
- Affiliations
-
- 1Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea. jinhwalee@ewha.ac.kr
Abstract
- Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
- Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
- Erlotinib-Related Spontaneous Pneumothorax in Patient with Primary Lung Cancer
